Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2018

Open Access 01-01-2018 | Original Article

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study

Authors: Maarten Arends, Simon Körver, Derralynn A. Hughes, Atul Mehta, Carla E. M. Hollak, Marieke Biegstraaten

Published in: Journal of Inherited Metabolic Disease | Issue 1/2018

Login to get access

Abstract

Quality of life (QoL) is decreased in patients with Fabry disease (FD). To improve QoL, it is important to understand the influence of FD related characteristics, symptoms, and complications. In this retrospective cohort study we explored the effect of pain (measured by the Brief Pain Inventory), phenotype, treatment, and FD-related complications on QoL. QoL data of Fabry patients as assessed by the EuroQol five dimension questionnaire (EQ-5D) from two international centers of excellence were collected. The aim of this study was to evaluate the effect of sex, phenotype, age, different states of disease severity, pain, and ERT on EQ-5D utilities. For 286 adult FD patients (mean age 42.5 years, 40% men, 60% classical phenotype) 2240 EQ-5Ds were available. QoL is decreased in men as well as women with FD, especially in older men with a classical phenotype. At age 50, utility was lower in men with classical FD compared to those with non-classical disease (β = −0.12, 95% CI: -0.23 – 0.01, p = 0.037) with further difference in the years thereafter. Cardiovascular complications, stroke or transient ischemic attacks, multiple FD-related complications and pain were also associated with decreased utilities. Overall, no change in utility was seen in patients on ERT over a mean follow-up of 6.1 years. FD leads to a decreased QoL compared to the general population. Disease complications and pain both negatively influence QoL. Adequate assessment and treatment of pain as well as improved strategies to prevent disease complications are needed to improve QoL in the FD population.
Appendix
Available only for authorised users
Literature
go back to reference Angelini C (2015) Spectrum of metabolic myopathies. Biochim Biophys Acta 1852:615–621CrossRef Angelini C (2015) Spectrum of metabolic myopathies. Biochim Biophys Acta 1852:615–621CrossRef
go back to reference Arends M, Hollak CE, Biegstraaten M (2015) Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis 10:77CrossRef Arends M, Hollak CE, Biegstraaten M (2015) Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis 10:77CrossRef
go back to reference Arends M, Wanner C, Hughes D et al (2016) Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 28:1631–1641CrossRef Arends M, Wanner C, Hughes D et al (2016) Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 28:1631–1641CrossRef
go back to reference Biegstraaten M, Hollak CE, Bakkers M, Faber CG, van Schaik IN (2012) Small fiber neuropathy in Fabry disease. Mol Genet Metab 106:135–141CrossRef Biegstraaten M, Hollak CE, Bakkers M, Faber CG, van Schaik IN (2012) Small fiber neuropathy in Fabry disease. Mol Genet Metab 106:135–141CrossRef
go back to reference Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23:129–138PubMed Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23:129–138PubMed
go back to reference Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRef Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRef
go back to reference EuroQol-Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef EuroQol-Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
go back to reference Gold H, Mirzaian M, Dekker N et al (2013) Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin Chem 59:547–556CrossRef Gold H, Mirzaian M, Dekker N et al (2013) Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin Chem 59:547–556CrossRef
go back to reference Gold KF, Pastores GM, Botteman MF et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317–327CrossRef Gold KF, Pastores GM, Botteman MF et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317–327CrossRef
go back to reference Gungor D, Kruijshaar ME, Plug I et al (2016) Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis 39:253–260CrossRef Gungor D, Kruijshaar ME, Plug I et al (2016) Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis 39:253–260CrossRef
go back to reference Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRef Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRef
go back to reference Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42:247–252CrossRef Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42:247–252CrossRef
go back to reference Hoffmann B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5:1447–1453CrossRef Hoffmann B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5:1447–1453CrossRef
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 3:1–150 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 3:1–150
go back to reference Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736–741CrossRef Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736–741CrossRef
go back to reference Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ (2006) The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 15:1121–1132CrossRef Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ (2006) The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 15:1121–1132CrossRef
go back to reference Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ (2005) Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 149:1574–1578PubMed Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ (2005) Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 149:1574–1578PubMed
go back to reference Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRef Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRef
go back to reference MacDermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775CrossRef MacDermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775CrossRef
go back to reference MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760CrossRef MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760CrossRef
go back to reference Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Investig 34:236–242CrossRef Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Investig 34:236–242CrossRef
go back to reference Miller FG, Colloca L, Kaptchuk TJ (2009) The placebo effect: illness and interpersonal healing. Perspect Biol Med 52:518–539CrossRef Miller FG, Colloca L, Kaptchuk TJ (2009) The placebo effect: illness and interpersonal healing. Perspect Biol Med 52:518–539CrossRef
go back to reference Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD (2002) Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 11:127–133 Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD (2002) Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 11:127–133
go back to reference O’Brien T, Breivik H (2012) The impact of chronic pain: European patients' perspective over 12 months. Scand J Pain 3:23–29CrossRef O’Brien T, Breivik H (2012) The impact of chronic pain: European patients' perspective over 12 months. Scand J Pain 3:23–29CrossRef
go back to reference Politei JM, Bouhassira D, Germain DP et al (2016) Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther 22:568–576CrossRef Politei JM, Bouhassira D, Germain DP et al (2016) Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther 22:568–576CrossRef
go back to reference Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343CrossRef Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337–343CrossRef
go back to reference Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG (2013a) Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis 8:1–9CrossRef Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG (2013a) Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis 8:1–9CrossRef
go back to reference Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013b) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47CrossRef Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013b) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47CrossRef
go back to reference Schiffmann R, Kopp JB, Austin IH et al (2001) Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 285:2743–2749CrossRef Schiffmann R, Kopp JB, Austin IH et al (2001) Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 285:2743–2749CrossRef
go back to reference Schuller Y, Linthorst GE, Hollak CEM, Van Schaik IN, Biegstraaten M (2016) Pain management strategies for neuropathic pain in Fabry disease—a systematic review. BMC Neurol 16:16–25 Schuller Y, Linthorst GE, Hollak CEM, Van Schaik IN, Biegstraaten M (2016) Pain management strategies for neuropathic pain in Fabry disease—a systematic review. BMC Neurol 16:16–25
go back to reference Smid BE, van der Tol L, Cecchi F et al (2014) Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol 177:400–408CrossRef Smid BE, van der Tol L, Cecchi F et al (2014) Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol 177:400–408CrossRef
go back to reference Street NJ, Yi MS, Bailey LA, Hopkin RJ (2006) Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med 8:346–353CrossRef Street NJ, Yi MS, Bailey LA, Hopkin RJ (2006) Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med 8:346–353CrossRef
go back to reference Uceyler N, Ganendiran S, Kramer D, Sommer C (2014) Characterization of pain in fabry disease. Clin J Pain 30:915–920CrossRef Uceyler N, Ganendiran S, Kramer D, Sommer C (2014) Characterization of pain in fabry disease. Clin J Pain 30:915–920CrossRef
go back to reference van der Tol L, Cassiman D, Houge G et al (2014) Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep 17:83–90CrossRef van der Tol L, Cassiman D, Houge G et al (2014) Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep 17:83–90CrossRef
go back to reference Wagner M, Krämer J, Blohm E et al (2014) Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease. BMC Nephrol 15:1–8CrossRef Wagner M, Krämer J, Blohm E et al (2014) Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease. BMC Nephrol 15:1–8CrossRef
go back to reference Walters SJ, Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14:1523–1532CrossRef Walters SJ, Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14:1523–1532CrossRef
go back to reference Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45CrossRef Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45CrossRef
go back to reference Watt T, Burlina AP, Cazzorla C et al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12:703–712CrossRef Watt T, Burlina AP, Cazzorla C et al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12:703–712CrossRef
go back to reference Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128CrossRef Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128CrossRef
go back to reference Żuraw W, Golicki D, Jurecka A, Tylki-Szymańska A (2011) Quality of life among polish Fabry patients—a cross-sectional study quality of life among polish Fabry patients. Cent Eur J Med 6:741–749 Żuraw W, Golicki D, Jurecka A, Tylki-Szymańska A (2011) Quality of life among polish Fabry patients—a cross-sectional study quality of life among polish Fabry patients. Cent Eur J Med 6:741–749
Metadata
Title
Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
Authors
Maarten Arends
Simon Körver
Derralynn A. Hughes
Atul Mehta
Carla E. M. Hollak
Marieke Biegstraaten
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 1/2018
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0095-6

Other articles of this Issue 1/2018

Journal of Inherited Metabolic Disease 1/2018 Go to the issue